Nemolizumab

Nemolizumab
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration	Subcutaneous injection
Pregnancy category
Bioavailability
Metabolism	Proteolytic enzymes
Elimination half-life
Excretion
Legal status	Investigational
CAS Number	1476039-58-3
PubChem
DrugBank
ChemSpider	none
KEGG	D11080

Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis.<ref>H. Spreitzer,

 Neue Wirkstoffe - Nemolizumab, 
 Österreichische Apothekerzeitung,</ref> It is a monoclonal antibody that blocks the interleukin-31 receptor A.<ref>, 
 International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 74, 
 WHO Drug Information, 
 2015,
 Vol. 29(Issue: 3),
 
 
 
 
 
 Full text,</ref> Results of a Phase II clinical trial were published in March 2017.<ref>, 
 Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis, 
 New England Journal of Medicine, 
 2017,
 Vol. 376(Issue: 9),
 pp. 826–835,
 DOI: 10.1056/NEJMoa1606490,
 PMID: 28249150,</ref>

Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.<ref> ,

 Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma Full text, 
 , 
 Pharmabiz.com, 
 22 July 2016,

</ref>

References

   This article is a dermatologic drug stub. You can help WikiMD by expanding it!

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!

   This article is a medical stub. You can help WikiMD by expanding it!